| M |
2026-01-05 |
2026-01-02 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$66.10 |
-13.2K |
3.80M |
-0.3% |
-$871.7K |
| DM |
2025-12-30 |
2025-12-29 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale+OE |
$69.13 |
-51.7K |
3.82M |
-1% |
-$3.58M |
| DM |
2025-12-30 |
2025-12-29 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$6.15 |
+51.7K |
3.84M |
+1% |
+$318.1K |
| M |
2025-12-23 |
2025-12-19+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$68.04 |
-26.0K |
3.81M |
-0.7% |
-$1.77M |
| M |
2025-12-19 |
2025-12-17 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$64.04 |
-85.0K |
3.87M |
-2% |
-$5.44M |
| M |
2025-12-16 |
2025-12-15+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$67.00 |
-184.3K |
3.92M |
-4% |
-$12.35M |
|
2025-12-16 |
2025-12-12 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
A - Grant |
$0.00 |
+180.0K |
4.10M |
+5% |
$0 |
| M |
2025-04-11 |
2025-04-09+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$10.87 |
-141.1K |
4.03M |
-3% |
-$1.53M |
|
2025-03-17 |
2025-03-13 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$15.07 |
-51.4K |
4.06M |
-1% |
-$775.0K |
|
2025-03-17 |
2025-03-13 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
A - Grant |
$0.00 |
+340.0K |
4.11M |
+9% |
$0 |
| DM |
2025-03-05 |
2025-03-03+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$7.75 |
+300.0K |
3.94M |
+8% |
+$2.33M |
| DM |
2025-03-05 |
2025-03-03+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale+OE |
$17.58 |
-300.0K |
3.77M |
-7% |
-$5.27M |
|
2025-02-10 |
2025-02-07 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
A - Grant |
$20.10 |
+9,550 |
3.77M |
+0.3% |
+$192.0K |
|
2025-01-06 |
2025-01-02 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$19.05 |
-11.5K |
3.76M |
-0.3% |
-$219.5K |
|
2024-12-23 |
2024-12-23 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$19.59 |
-12.6K |
3.78M |
-0.3% |
-$246.1K |
| M |
2024-12-20 |
2024-12-18 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$21.24 |
-26.7K |
3.69M |
-0.7% |
-$567.5K |
|
2024-12-20 |
2024-12-18 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
A - Grant |
$0.00 |
+100.0K |
3.79M |
+3% |
$0 |
| D |
2024-02-02 |
2024-01-31 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$14.54 |
+57.5K |
3.77M |
+2% |
+$836.0K |
| DM |
2024-02-02 |
2024-01-31 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale+OE |
$32.35 |
-57.5K |
3.73M |
-2% |
-$1.86M |
| M |
2024-01-04 |
2024-01-02 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$31.01 |
-9,952 |
3.72M |
-0.3% |
-$308.6K |
|
2023-12-22 |
2023-12-20 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$28.54 |
-12.0K |
3.73M |
-0.3% |
-$342.5K |
|
2023-10-27 |
2023-10-25 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$24.21 |
-24.3K |
3.74M |
-0.6% |
-$589.2K |
| DM |
2023-09-20 |
2023-09-18 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale+OE |
$28.12 |
-57.8K |
3.76M |
-2% |
-$1.62M |
| D |
2023-09-20 |
2023-09-18 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$4.75 |
+57.8K |
3.82M |
+2% |
+$274.3K |
| DM |
2023-05-05 |
2023-05-03+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale+OE |
$39.32 |
-104.9K |
3.76M |
-3% |
-$4.13M |
| DM |
2023-05-05 |
2023-05-03+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$2.01 |
+104.9K |
3.81M |
+3% |
+$210.9K |
| M |
2022-12-20 |
2022-12-16+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
A - Grant |
$0.00 |
+252.4K |
3.72M |
+7% |
$0 |
| M |
2022-09-29 |
2022-09-27 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$30.79 |
-40.6K |
3.47M |
-1% |
-$1.25M |
|
2022-07-12 |
2022-07-08 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
D - Sale to Iss |
$0.00 |
-551.2K |
3.51M |
-14% |
$0 |
| D |
2022-07-11 |
2022-07-07 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$14.54 |
+2,501 |
4.06M |
+0.1% |
+$36.4K |
| DM |
2022-02-14 |
2022-02-11 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale+OE |
$51.91 |
-146.4K |
4.16M |
-3% |
-$7.60M |
| D |
2022-02-14 |
2022-02-11 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$5.19 |
+146.4K |
4.20M |
+4% |
+$759.8K |
| D |
2022-01-07 |
2022-01-07 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$5.19 |
+11.8K |
4.06M |
+0.3% |
+$61.3K |
|
2022-01-04 |
2022-01-01 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
A - Grant |
$0.00 |
+800.0K |
4.05M |
+25% |
$0 |
| D |
2021-12-23 |
2021-12-23 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
M - OptEx |
$5.19 |
+11.8K |
3.25M |
+0.4% |
+$61.3K |
| M |
2021-12-17 |
2021-12-15 |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$67.56 |
-60.0K |
3.25M |
-2% |
-$4.05M |
| M |
2021-10-22 |
2021-10-20+ |
ARWR |
ARROWHEAD PHARMACEUTICALS, INC. |
Anzalone Christopher Richard |
CEO, Dir |
S - Sale |
$65.77 |
-65.0K |
3.28M |
-2% |
-$4.27M |